AI-driven tools now enable regulatory affairs (RA) professionals to perform faster, more accurate, and proactive regulatory impact assessments. This blog explores how AI can be leveraged to transform impact analysis, ensuring better compliance, lower risk, and more strategic decision-making across both pharma and med device sectors.

Regulatory Impact Assessment (RIA) is the structured process of evaluating how changes in regulations will affect a company’s products, processes, or operations. It’s a critical task in regulatory affairs, especially in heavily regulated sectors like pharmaceuticals and medical devices.

A robust RIA typically involves:

• Identifying relevant regulatory changes
• Mapping affected products, markets, and documentation
• Analyzing the scope and depth of required updates
• Developing action plans to maintain compliance

Without timely and accurate RIA, companies risk non-compliance, product recalls, market withdrawal, or reputational damage.

Challenges of Traditional RIA Methods

Despite its importance, many companies still rely on manual tools – like spreadsheets, emails, and isolated document repositories – for their impact assessments. This traditional approach presents several challenges:

1. Lack of Real-Time Regulatory Intelligence

Staying updated on global regulatory changes is difficult and time-consuming. Manual tracking often results in missed updates or delayed responses.

2. Siloed Data and Communication

Regulatory, clinical, labeling, and quality teams often operate in silos, making it hard to identify the full scope of impact from a single regulatory change.

3. Inconsistent Impact Mapping

Without automated tools, mapping changes to the right products, submissions, and geographies is prone to human error and inefficiencies.

4. Reactive Rather Than Proactive

Most manual RIA processes are reactive, starting only after a regulatory update has already been published – often with tight compliance deadlines.

These limitations can cost time, resources, and, in some cases, market access.

How AI Enhances Regulatory Impact Assessment

Artificial Intelligence addresses the shortcomings of traditional RIA by introducing speed, scale, and intelligence. Here’s how AI transforms the process:

1. Automated Regulatory Monitoring

AI tools continuously scan global regulatory databases and health authority websites for new or updated regulations. Using Natural Language Processing (NLP), they interpret and classify the relevance of each change.

2. Intelligent Impact Mapping

AI algorithms automatically link new regulatory updates to relevant product dossiers, clinical documents, and labeling records using metadata and historical submission data.

3. Risk-Based Prioritization

AI assesses the severity and potential impact of each change, helping RA teams prioritize their responses based on compliance urgency and business risk.

4. Cross-Functional Alerts and Collaboration

AI-enabled platforms notify all affected departments and stakeholders, triggering workflows and collaborative response strategies within an integrated environment.

By leveraging these capabilities, pharma and med device companies can shift from reactive to proactive compliance strategies.

Use Case: AI-Driven RIA in Pharma

A large pharmaceutical company used Visu AI-powered RIA platform to analyze EU regulation changes related to safety signal reporting. The AI tool:

• Flagged the changes within hours of publication
• Automatically matched them to several active products
• Highlighted discrepancies in safety documentation
• Triggered updates to pharmacovigilance submissions

Result: Compliance achieved within 10 business days – compared to the typical 4-6 week manual process.

Use Case: AI-Driven RIA in Medical Devices

A med device company preparing for MDR submissions implemented Visu AI-driven RIA platform to manage ongoing updates from EU Notified Bodies. The tool:

• Scanned MDR-related publications and issued alerts within 24 hours
• Automatically mapped updates to device categories and impacted documentation
• Flagged labeling inconsistencies across regions
• Generated prioritized action plans for each impacted product family

Result: The company avoided non-compliance and maintained uninterrupted market access in all target EU countries.

Key Benefits of Leveraging AI in Regulatory Impact Assessment

Integrating AI into the RIA process delivers numerous advantages that align with the operational and compliance goals of pharma and med device regulatory teams:

1. Speed and Efficiency

AI can reduce the time required for impact assessments from weeks to hours. By automating information gathering, mapping, and triaging tasks, RA teams save valuable time and resources.

2. Improved Accuracy

AI minimizes human error by consistently interpreting regulatory texts, identifying affected assets, and ensuring no critical detail is missed. This leads to higher confidence in compliance decisions.

3. Enhanced Compliance

With real-time alerts and impact analysis, companies can respond swiftly to changes, avoiding missed deadlines, audit findings, and penalties.

4. Better Resource Allocation

AI helps prioritize actions based on risk and impact severity. This allows teams to focus on high-risk areas while managing less urgent tasks more efficiently.

5. Scalable Global Operations

For global companies managing dozens or hundreds of product lines across multiple jurisdictions, AI enables scalability in impact analysis without needing to scale headcount linearly.

These benefits create a more resilient, agile, and forward-thinking regulatory function – essential in an industry where agility is a competitive advantage.

AI Tools and Technologies Powering RIA

To understand how AI actually works in practice for RIA, let’s look at the technologies and capabilities that make it possible:

• Natural Language Processing (NLP): Enables AI to understand regulatory language and assess the context of changes.
• Machine Learning (ML): Learns from historical data to improve the accuracy and relevance of future impact assessments.
• Agentic-AI : Multiple Agents talking to each other and making decisions and/or setting actions.
• Predictive Analytics: Forecasts potential downstream impacts and timelines based on previous similar changes.

Combined, these technologies form the engine of intelligent regulatory insight and automated decision support.

The Future of AI in Regulatory Impact Assessment

Looking ahead, AI’s role in regulatory affairs will only deepen. We can expect even more advanced capabilities such as:

• Conversational AI Assistants: Guiding RA professionals through real-time impact assessments.
• Dynamic Compliance Dashboards: Offering live updates, risk scores, and predictive recommendations.
• AI-Driven Regulatory Strategy Development: Supporting global launch planning based on evolving regulatory landscapes.

As AI evolves, the future of regulatory affairs will be faster, smarter, and more integrated – making impact assessments an agile strategic tool rather than a reactive compliance requirement.

For pharmaceutical and medical device companies navigating complex, evolving global regulations, Regulatory Impact Assessment is a non-negotiable pillar of compliance. However, the traditional manual approach is no longer viable for modern business demands.

AI offers a smarter way forward. By automating data gathering, mapping impacts, and generating real-time insights, AI transforms RIA from a tedious chore into a strategic asset. Companies that adopt AI in this area will be better equipped to adapt quickly, maintain global compliance, and lead with confidence.

Now is the time for RA teams to embrace this digital transformation – not just to keep pace, but to lead the way in regulatory innovation.

• Improved Patient Safety.
• Streamlined Regulatory Compliance
• Enhanced Supply Chain Management
• Facilitated Post-market Surveillance

Global Implementation of UDI

The adoption of UDI is becoming increasingly important on a global scale. Various countries are in different stages of implementing UDI regulations, aligning with local requirements and international standards such as those set by the International Medical Device Regulators Forum (IMDRF). Below is a summary of countries that have implemented or are in the process of implementing UDI

This blog will explore the importance of eDMS in the medical device industry, with a focus on how regulatory eDMS solutions help companies meet compliance requirements efficiently. If your company is navigating the complex landscape of regulatory submissions, audits, and quality management, a well-implemented eDMS can be your secret weapon.

What is eDMS in the Medical Device Industry?

Defining eDMS

An electronic Document Management System (eDMS) is a software solution designed to manage, store, track, and share electronic documents in a secure environment. In the medical device sector, an eDMS is not just a repository for documents—it plays a critical role in ensuring that all documentation related to the design, manufacture, testing, and regulation of medical devices is properly organized and accessible for audits, approvals, and regulatory submissions.

Regulatory eDMS

A regulatory eDMS is a specialized type of eDMS that focuses on managing documents needed for regulatory compliance, such as submissions to the FDA, European Medicines Agency (EMA), and other global regulatory bodies. This system helps medical device companies manage regulatory documents efficiently, ensuring that they adhere to the standards required by governing bodies.

The Importance of Regulatory eDMS in Medical Devices

Ensuring Compliance with Regulatory Standards

Medical device companies must comply with a wide array of regulations, including FDA 21 CFR Part 11, ISO 13485, and the EU Medical Device Regulation (MDR). These regulations require companies to maintain detailed records of device development, clinical trials, quality assurance processes, and more. A regulatory eDMS ensures that all these documents are stored securely and are readily accessible for regulatory reviews or audits.

Streamlining Regulatory Submissions

Submitting regulatory documentation is one of the most time-consuming tasks in the medical device industry. A regulatory eDMS simplifies the process by automating document workflows, maintaining version control, and ensuring that documents meet the specific formatting and content requirements of various regulatory bodies.

For example, when submitting a premarket approval (PMA) to the FDA, a regulatory eDMS can ensure that all necessary documentation is compiled accurately, reducing the risk of delays caused by missing or incorrect information.

Key Features of an Effective eDMS for Medical Devices

1. Document Version Control

Medical device development involves a series of iterations, revisions, and updates to design and manufacturing documents. An eDMS system must provide robust version control to track these changes. This ensures that teams are always working with the latest version of a document, reducing confusion and the risk of non-compliance.

2. Automated Workflows

Automating workflows is a game-changer for regulatory compliance. With an eDMS, tasks like document approvals, reviews, and submissions can be automated, ensuring timely completion and reducing the administrative burden. Automated workflows also allow for clear tracking of who accessed or edited a document, ensuring accountability.

3. Audit Trails

Regulatory bodies require thorough audit trails to confirm that changes to documents are tracked and recorded properly. An eDMS provides an electronic log of every interaction with a document – when it was created, edited, approved, or shared—allowing for complete transparency and traceability.

4. Secure Access and Permissions

Given the sensitive nature of regulatory documents, it is vital that an eDMS offers role-based access control. This means that only authorized personnel can access or modify certain documents, safeguarding against unauthorized changes and protecting intellectual property.

How eDMS Enhances Regulatory Compliance for Medical Devices

Managing Regulatory Documents Efficiently

In the medical device industry, regulatory submissions require extensive documentation, including design dossiers, risk management reports, and clinical evaluations. A regulatory eDMS ensures that all required documents are organized and accessible, making the submission process more efficient and reducing the risk of delays due to missing documentation.

Supporting Global Compliance

For medical device companies operating in multiple markets, compliance with various international regulations can be challenging. Regulatory requirements vary significantly across regions, such as the FDA’s requirements in the United States versus the MDR in the European Union. A regulatory eDMS can be configured to support different sets of regulations, helping companies maintain compliance across multiple markets simultaneously.

Facilitating Faster Audits and Inspections

Regulatory bodies frequently conduct audits and inspections to ensure compliance with relevant standards. With a regulatory eDMS, audit trails, document versions, and submission records are easily accessible, making it faster and more straightforward to respond to audits and inspections. The ability to produce the right document quickly and demonstrate regulatory adherence can significantly improve audit outcomes.

Benefits of Implementing eDMS for Medical Devices

1. Increased Efficiency

Manual document management processes are often inefficient and prone to error. With an eDMS, medical device companies can significantly reduce the time spent on document handling, approvals, and submissions. Automated workflows and electronic submissions reduce the administrative workload, allowing teams to focus on product innovation and development.

2. Improved Collaboration

In a globally dispersed industry, teams across multiple locations need access to the same documents. A cloud-based eDMS allows seamless collaboration between different teams, ensuring that everyone has access to up-to-date regulatory documents. This eliminates the delays caused by sharing documents via email or physical copies and ensures everyone is on the same page.

3. Reduced Risk of Non-Compliance

One of the biggest risks in the medical device industry is non-compliance, which can lead to costly recalls, fines, or even legal action. An eDMS reduces this risk by maintaining accurate, up-to-date records of all regulatory documents. Automated workflows ensure that necessary approvals are obtained, and audit trails provide the transparency needed to prove compliance.

4. Cost Savings

While implementing an eDMS requires an initial investment, the long-term cost savings are significant. By reducing the time spent on manual document management, automating workflows, and minimizing the risk of regulatory penalties, medical device companies can save both time and money.

Challenges of Implementing eDMS in Medical Device Companies

1. Initial Setup and Configuration

Implementing an eDMS can be complex, particularly for companies that are new to electronic systems or have extensive legacy documentation. The initial setup requires careful planning, including digitizing existing documents, configuring workflows, and training staff.

2. Change Management

Transitioning from a paper-based or hybrid document management system to a fully electronic system can be a cultural shift for some organizations. Ensuring that staff are adequately trained and that there is buy-in from all levels of the organization is critical to the successful implementation of an eDMS.

3. Integration with Existing Systems

For an eDMS to be effective, it needs to integrate with other systems used in the product lifecycle, such as Quality Management Systems (QMS), Enterprise Resource Planning (ERP), and Clinical Trial Management Systems (CTMS). Ensuring seamless integration between these systems is essential for maximizing the benefits of an eDMS.

How to Choose the Right eDMS for Regulatory Compliance

Assess Your Specific Needs

Not all eDMS platforms are created equal. Medical device companies need to choose a system that aligns with their specific regulatory requirements and business processes. Consider factors like the scale of your operations, the number of users, and the level of customization needed.

Evaluate Features for Regulatory Compliance

Ensure that the eDMS you choose offers features like version control, audit trails, secure access, and regulatory submission management. These are essential for ensuring compliance and avoiding potential regulatory issues down the line.

Consider Cloud-Based Solutions

Many medical device companies are opting for cloud-based eDMS solutions, which offer greater flexibility, scalability, and cost savings compared to on-premises systems. Cloud-based systems are particularly advantageous for companies with global operations, as they allow for real-time collaboration and easy access to documents from anywhere in the world.

The Future of eDMS in the Medical Device Industry

AI and Automation

As technology continues to evolve, eDMS systems are likely to incorporate more AI and automation features. These advancements could include automated document generation, predictive analytics for regulatory submissions, and AI-powered compliance monitoring.

Blockchain for Document Security

Blockchain technology has the potential to revolutionize the way documents are managed and secured. In the future, blockchain could be integrated into eDMS systems to provide an immutable, decentralized record of document versions and audit trails, further enhancing security and transparency.

Conclusion

An eDMS is more than just a digital filing cabinet – it’s a powerful tool that can transform the way medical device companies manage regulatory compliance. From ensuring accurate document version control to automating workflows and supporting global compliance, a well-implemented eDMS can help organizations stay competitive, compliant, and efficient in today’s fast-paced regulatory environment.

An UDI is a distinct numeric or alphanumeric code used to identify medical devices throughout healthcare supply chains. These codes are generated by product owners based on globally accepted standards for device identification.

The UDI code consists of two standard elements, which are:

• Device Identifier (DI): DI identifies the labeler and the model or version of a device. The DI is a required component and considered to be the static portion of the UDI, meaning that it is the same for all instances of the product model or version.
• Production Identifier (PI): PI identifies one or more variable characteristics, such as manufactured date, expiration date, lot number, or serial number. The PI is considered to be the dynamic portion of the UDI, meaning that the PI value changes according to the production controls.

The DI is always first and is followed by the PI if it has a value.

Unique Device Identifier (UDI) = Device Identifier (DI) + Production Identifier (PI)

There are different Issuing Agencies/ Entities for issuing an UDI for a medical device they are:

GS1: Global Standards 1 (GS1) are a nonprofit standards agency, GS1 sets international standards for supply chains, electronic data exchange, healthcare, and more. GTIN (Global Trade Item Number) and UPC (Universal Product Code) are GS1 standards, both are numeric only codes. GS1 provides a “GS1 Company Prefix” to a subscribing organization and reserves a range of “Item Reference” numbers for the organization to assign to their product portfolio. GS1 charges an initial fee and a lower annual renewal fee for the subscription. GS1 is used by the majority of medical device manufacturers.

HIBCC: Health Industry Business Communications Council (HIBCC) is a nonprofit organization focused on setting standards for the healthcare industry. The HIBC (Health Industry Bar Code) standard is managed by HIBCC and is an alphanumeric code. HIBCC provides a Labeler Identification Code (LIC) to an organization after paying a one-time subscription fee. The organization creates and assigns Product/Catalog Numbers (PCN) to their product portfolio without an additional charge.

ICCBBA: International Council for Commonality in Blood Banking Automation (ICCBBA) is a non-governmental organization. ICCBBA focuses exclusively on standards for medical products of human origin, such as blood products, tissues, and organs for transplant. It manages the ISBT 128 standard used in more than 75 countries. Only a few niche medical devices are identified using the ICCBBA standard.

Issuing Agency standards typically define a device identifier to encode a company, a product model, a package level, and a check character used to verify the accuracy of the code. 

UDI codes are included on the product and package labels and, in some cases, printed directly on the device itself. Regulations require the UDI be presented in both Automatic Identification and Data Capture (AIDC) and Human Readable Interpretation (HRI) formats.

The AIDC format is a one- or two-dimensional barcode. This format allows the product to be identified quickly and accurately by using barcode readers and scanner technologies. The HRI text format refers to easily readable text that allows the product to be identified by humans without the use of any scanning or barcode reader technology.

In the case of reused and reprocessed devices, such as a surgical scalpel, the UDI must be directly marked on the product, as the product packaging is discarded. There are different direct marking technologies such as laser etching, to mark the product for the life of the product.

Once the UDI is issued, the data must be securely stored in the manufacturer’s repository and submitted to the respective health authority’s Unique Device Identification Database (UDID).

In general, regulations require product UDI data to be reported to the UDID before the medical device is placed on the market. The UDI Device Identifier and numerous other data attributes need to be collected and submitted to the UDID.

An increasing number of health authorities are implementing UDI requirements to improve patient safety and the patient experience. Accurate, comprehensive product information gleaned from UDIDs is essential to ensure the correct and safe use of devices by all users, including patients, caregivers, healthcare providers, hospitals, and industry.

The primary goal of a UDI system is to ensure proper adverse event reporting among medical devices. UDI increases the accuracy of product traceability and enables medical device manufacturers, regulatory bodies, and other analysts to discover trends earlier and respond quicker in the event patient safety is at risk due to a certain device issue.

In order to effectively streamline UDI labeling and submissions for your medical devices, it is essential to have a thorough understanding of the entire process of development, validation, design, and submission of requirements. DDi offers a single Unique Device Identification (UDI) solution that meets compliance requirements across all countries.

In general, an eIFU is defined as a non-paper version of the instructions for use. Currently, the definition of an eIFU is not the same in each market.

In the EU, according to the Commission Implementing Regulation EU 2021/2226, which laid down rules for the application of Regulation (EU) 2017/745 of the European Parliament and of the Council in regards to electronic instructions for use of medical devices, instructions for use in electronic format means “instructions for use displayed in electronic form by the device, contained in portable electronic storage media supplied by the manufacturer together with the device, or made available through software or website.”

European eLabeling regulation 2021/2226 

The Medical Device Regulation (MDR) introduces a comprehensive framework that integrates multiple electronic instructions for use (eIFU) requirements, further supplemented by Implementing Regulation (EU) 2021/2226, the successor to Commission Regulation (EU) 207/2012.

Requirements for the use of electronic instructions for use as per regulation (EU) 2021/2226 

According to Implementing Regulation (EU) 2021/2226, instructions for use may be provided electronically (eIFU) instead of on paper if certain conditions are met:

1. The device should fall into a specific class, as mentioned below:
   • Implantable and active implantable medical devices and their accessories
   • Fixed installed medical devices and their accessories
   • Medical devices and their accessories fitted with a built-in system visually displaying the instructions for use (e.g., ultrasound equipment)
2. The devices and accessories are intended for exclusive use by professional users
3. The use by other  people is not reasonably foreseeable
4. For software, manufacturers may provide eIFUs within the software itself.

Manufacturers of Medical devices that provide instructions for use in electronic form to users instead of in paper form shall undertake a documented risk assessment which shall cover at least the following elements:

• Knowledge and experience of the intended users in particular regarding the use of the device and user needs;
• Characteristics of the environment in which the device will be used;
• knowledge and experience of the intended user of the hardware and software needed to display the instructions for use in electronic form;
• Access of the user to the reasonably foreseeable electronic resources needed at the time of use;
• Performance of safeguards to ensure that the electronic data and content are protected from tampering;
• Safety and backup mechanisms in the event of a hardware or software fault, particularly if the instructions for use in electronic form are integrated within the device;
• Foreseeable medical emergency situations requiring the provision of information in paper form;
• Impact caused by the temporary unavailability of the specific website, of the internet in general, or of their access in the healthcare institution, as well as the safety measures available to cope with such a situation;
• Evaluation of the period within which the instructions for use shall be provided in paper form at the user’s request;
• Assessment of the website’s compatibility with displaying the electronic instructions for use with different devices that could be used to display those instructions;
• Management of different versions of the instructions for use, where applicable

Factors to consider when switching to an electronic IFU for your medical device

1. Risk assessment

eIFU must maintain or improve the level of safety compared to providing a paper IFU. Your risk assessment needs to examine this carefully. For instance, if your device is sometimes used by nurses or doctors in rural locations where the internet may be spotty, what additional risks might that present? You will need to update your risk management procedures and forms to account for this.

2. Product packaging

The location of the eIFU must be indicated on the packaging for each unit or, in the case of fixed devices, on the device itself. For obvious reasons, you cannot simply place PDFs of your IFU on your website and assume professional users will know to look there. The Regulation makes it clear that your packaging must clearly specify that the IFU is in electronic format and where it can be found. Except for software and devices with screens, the IFU may reside on a website, and its location may be communicated via a website URL or QR code. If you choose the latter, make sure you document the pros and cons of using QR codes in your risk assessment and update your labeling work instructions as needed.

3. Validation

Ensure the user’s access is precise by having accurate product data in real-time and a solution for delivering the information in the user’s preferred language.

4. Method of delivery

If you make software as a medical device (SaMD) or a device with a larger display screen, the method of delivery may be the device itself. For all other devices, device manufacturers will most likely deliver IFUs via their website. This fulfills a key requirement that the information be provided in a universally available format (thumb drives and DVDs are no longer universal). The preamble of the new eIFU regulation says, “To ensure unconditional access to the instructions for use in electronic form and to facilitate the communication of updates, those instructions should be available on the website of the manufacturer in an official language of the Union determined by the Member State in which the device is made available to the user or patient.” This does not mean you cannot deliver your eIFU on a private YouTube channel, for example.

5. Paper version

There are professionals out there who prefer paper-based instructions, or (it is true) might not have reliable internet access. It is EU law to have paper IFUs, with the exception of some devices. If a paper-based option is required, you are obligated to provide a paper version within seven calendar days of the request at no cost. In cases where video or animation is not used, the eIFU may simply be a printed copy of the PDF you maintain online. Make sure to update your labeling SOP with this requirement.

6. Online security

Making your IFU available online is easy. Ensuring that it does not accidentally get removed or replaced is not possible. You will need to put procedures in place to ensure that your sales and marketing departments do not change the URL, delete old versions, or otherwise change the document. You should really think of the master IFU web page(s) as controlled documents, not just the IFU itself.

7. Archival procedures

For devices without a defined expiration date, your IFU needs to be maintained for 15 years after the last device has been placed on the market. For devices with an expiration date, this changes to 10 years. You also need to have a system for indicating when changes have been made (change control) and a way to inform each user if the change was made for safety reasons. Finally, all historical versions of the IFU must be made available on the website.

8. Privacy policy

Europe has one of the strictest online privacy laws in the world, known simply as the GDPR (General Data Protection Regulation 2016/679). If you will be asking the user to provide their name and/or email, or if your website has cookies enabled (most do), you will need to make sure you are following the GDPR.

Advantages of eIFU over paper-based instructions:

• Enhanced accessibility: considering the high internet coverage, electronic instructions can be accessed digitally and consulted anywhere, providing easier search and navigation and greater flexibility.
• Real-time updates: eIFU allows for immediate updates and revisions, ensuring that users always have the latest information about the product they are using. This is crucial for patient safety and optimal device utilization.
• User-friendly interfaces: Electronic formats enable the incorporation of multimedia elements, such as videos and interactive features, enhancing the clarity and effectiveness of instructions.
• Increased efficiency in MDR implementation: electronic formats facilitate the inclusion of multiple languages and therefore contribute to reducing the risk of shortages of medical devices and improving the overall availability of these devices, especially in a multilingual context like the European Union.
• Cost efficiency: Over time, the implementation of eIFU can lead to cost savings for both manufacturers and healthcare institutions, as the need for printing, distribution, storage, and waste management of paper IFU is significantly reduced.
• Environmentally sustainable: The transition to eIFU aligns with broader efforts to reduce paper usage, contributing to environmental sustainability and supporting the EU Green Deal.

Going forward, manufacturers seeking to sell their products in the European market must comply with the EU eIFU regulations. Adhering to these regulations will provide greater flexibility and reduce the risk of product recalls related to IFUs. If you are in the process of updating your device labels and preparing eIFUs, feel free to contact DDi for expert assistance.